Obstrüktif Uyku Apne Sendromunda İnflamasyon ve Metabolik Sendrom
Özet
Obstrüktif Uyku Apne Sendromu (OUAS) ve metabolik sendrom, kardiyovasküler ve serebrovasküler hastalık riskini artıran ve birbiriyle karmaşık, iki yönlü ilişkileri olan klinik tablolardır. OUAS, uyku sırasında tekrarlayan farengeal havayolu tıkanıklıkları, aralıklı hipoksi ve uyku bölünmeleri ile karakterizedir. Bu durum, visseral yağ dokusundan proinflamatuar sitokinlerin (IL-6, TNF-α) ve karaciğerden CRP salınımını tetikleyerek sistemik inflamasyona yol açar. Metabolik sendromun abdominal obezite, hipertansiyon, dislipidemi ve yüksek açlık kan şekeri gibi tanı kriterlerinin her biri OUAS ile yakından ilişkilidir. Obezite, üst solunum yolunu mekanik olarak daraltıp leptin direncini artırarak OUAS riskini yükseltirken; OUAS da uyku yoksunluğu, ghrelin artışı ve kortizol salınımı mekanizmalarıyla kilo alımını ve viseral yağlanmayı teşvik eder. Aralıklı hipoksi, sempatik sinir sistemi aktivasyonuna, beta hücre disfonksiyonuna, insülin direncine ve renin-anjiyotensin-aldosteron sistemi uyarımına neden olarak dirençli hipertansiyon ve tip 2 diyabet gelişimine zemin hazırlar. Ayrıca karaciğerde lipid biyosentezini etkileyerek dislipidemiye ve sonuç olarak karotis intima-media kalınlığında artışla birlikte koroner arter hastalığı riskine yol açar. CPAP tedavisi, sempatik tonusu, anjiyotensin düzeylerini ve viseral yağlanmayı azaltarak bu metabolik dengesizliklerin düzeltilmesinde ve kardiyovasküler riskin düşürülmesinde önemli bir rol oynamaktadır. Dolayısıyla, "Sendrom Z" olarak da adlandırılan bu iki tablonun tedavisinde OUAS'ın mutlaka göz önünde bulundurulması gerekir.
Obstructive Sleep Apnea Syndrome (OSAS) and metabolic syndrome are interrelated clinical conditions that significantly elevate the risk of cardiovascular and cerebrovascular diseases through complex, bidirectional mechanisms. OSAS is characterized by recurrent pharyngeal airway obstructions, intermittent hypoxia, and sleep fragmentation. This condition triggers systemic low-grade inflammation by increasing proinflammatory cytokines such as IL-6 and TNF-α, which are primarily secreted from visceral adipose tissue, along with elevated CRP levels. Each component of metabolic syndrome—including abdominal obesity, hypertension, dyslipidemia, and impaired glucose metabolism—shares a strong link with OSAS. While obesity mechanically narrows the upper airway and induces leptin resistance to worsen OSAS, OSAS itself promotes weight gain and visceral adiposity through sleep restriction, increased ghrelin secretion, and chronic cortisol elevation. Intermittent hypoxia stimulates the sympathetic nervous system, activates the renin-angiotensin-aldosterone system, and impairs pancreatic beta-cell function, thereby driving insulin resistance, type 2 diabetes, and resistant hypertension. Furthermore, prolonged hypoxia alters lipid metabolism by upregulating transcription factors in the liver, leading to dyslipidemia, increased carotid intima-media thickness, and an elevated risk of myocardial infarction. Continuous Positive Airway Pressure (CPAP) therapy plays a crucial role in mitigating these risks by reducing sympathetic tone, angiotensin levels, and visceral fat. Consequently, managed collectively as "Syndrome Z," effective OSAS treatment is vital for optimizing metabolic and cardiovascular health.
Referanslar
Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am. 2104;43(1):1-23. Doi: 10.1016/j.ecl.2013.09.009.
Engin A. The definition and prevalance of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1-17. Doi: 10.1007/978-3-319-48382-5_1.
Gündogan K, Bayram F, Capak M, et al. Prevalance of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia. Metab Syndr Relat Disord. 2009;7(5):427-434. Doi: 10.1089/met.2008.0068.
Wilcox I, McNamara SG, Collins FL, et al. “Syndrome Z”: the interaction of sleep apnoea, vascular risk factors and heart disease. Thorax. 1998;53(suppl 3):S25-28.
Clinton JM, Davis CJ, Zielinski MR, et al. Biochemical regulation of sleep and sleep biomarkers. J Clin Sleep Med. 2011;7(Suppl):S38-42. Doi: 10.5664/JCSM.1360.
Vgontzas AN, Zoumakis E, Bixler EO, et al. Selective effects of CPAP on sleep apnoea-associated manifestations. Eur J Clin Invest. 2008;38(8):585-595. Doi:10.1111/j.1365-2362.2008.01984.x.
Kritikou I, Basta M, Vgontzas AN, et al. Sllep apnoea, sleepiness, inflammation and insülin resistance in middle-aged males and females. Eur Respir J. 2014;43(1):145-155. Doi: 10.1183/09031936.00126712.
Vicente E, Marin JM, Carrizo SJ, et al. Upper airway and systemic inflammation in obstructive sleep apnoea. Eur Respir J.2016;48(4):1108-1117. Doi:10.1183/13993003.00234-2016.
Meier-Ewert HK, Ridker PM, Rifai N, et al. Absence of diurnal variation of C-rective protein concentrations in healthy human subjects. Clin Chem. 2001;47(3):426-430.
Gozal D, Kheirandish-Gozal L, Bhattacharjee R, et al. C-reactive protein and obstructive sleep apnea syndrome in children. Front Biosci. 2012;4:2410-2422. Doi: 10.2741/e553.
Zelova H, Hosek J. TNF-α signalling and inflammation: interactions between old acquaintances. Inflamm Res. 2013;62:641-651. Doi: 10.1007/s00011-013-0633-0.
Nadeem R, Molnar J, Madbouly EM, et al. Serum inflammatory markers in obstructive sleep apnea: a meta-analysis. J Clin Sleep Med. 2013;9:1003-1012. Doi: 10.5664/jcsm.3070.
Minoguchi K, Yokoe T, Tanaka A, et al. Association between lipid peroxidation and inflammation in obstructive sleep apnoea. Eur Respir J. 2006;28(2):378-385. Doi: 10.1183/09031936.06.00084905.
Karamanlı H, Özol D, Ugur KS, et al. Influence of CPAP treatment on airway and systemic inflammation in OSAS patients. Sleep Breath. 2014;18(2):251-256. Doi: 10.1007/s11325-012.0761-8.
Quintas-Neves M, Preto J, Drummond M. Assessment of bariatric surgery efficacy on obstructive sleep apnea (OSA). Revista Portuguesa de Pneumologia. 2016;22(6):331-336. Doi: 10.1016/j.rppnen.2016.05.006.
Drager LF, Togeiro SM, Polotsky VY, et al. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol. 2013;62(7):569-576. Doi: 10.1016/j.jacc.2013.05.045.
Muscogiuri G, Barrea L, Annunziata G, et al. Obesity and sleep disturbance: the chicken or the egg? Crit Rev Food Sci Nutr. 2019;59(13):2158-2165. Doi:10.1080/10408398.2018.1506979.
Canuto R, Pattussi MP, Macagnan JBA, et al. Sleep deprivation and obesity in shift workers in southern Brazil. Public Health Nutr. 2014;17(11):2619-1623. Doi: 10.1017/S1368980013002838.
Kubo T, Oyama T, Nakamura K, et al. Retrospective cohort study of the risk of obesity among shift workers: Findings from the industry-based shift workers’health study, Japan. Occupational and Environmental Medicine. 2011;68(5):327-331. Doi: 10.1136/oem.2009.054445.
Cain SW, Filtness AJ, Phillips CL, et al. Enhanced preference for high-fat foods following a simulated night shift. Scan J Work Environ Health. 2015;41(3):288-293. Doi: 10.5271/sjweh.3486.
Simon SL, Field J, Miller LE, et al. Sweet/dessert foods are more appealing to adolescants after sleep restriction. PLoS One. 2015;10(2):e0115434. Doi: 10.1371/journal.pone.0115434.
Broussard JL, Van Cauter E. Disturbances of sleep and circadian rhythms: a novel risk factors for obesity. Curr Opin Endocrinol Diabetes Obes. 2016;23(5):353-359. Doi: 10.1097/MED.0000000000000276.
Vgontzas AN, Chrousos GP. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions an disturbances in sleep disorders. Endocrinol Mtab Clin North Am. 2002;31(1):15-36. Doi: 10.1016/S0889-8529(01)0000-6.
Ruan H, Xun P, Cai W, et al. Habitual sleep duration and risk of childhood obesity: systematic review and dose-response meta-analysis of prospective cohort studies. Sci Rep. 2015;5:16160. Doi: 10.1038/srep16160.
Kumari M, Badrick E, Ferrie J, et al. Self-reported sleep duration and sleep disturbance are indeperndently associated with cortisol secretion in the whitehall II study. J Clin Endocrinol Metab. 2009; 94(12):4801-4809. Doi: 10.1210/jc.2009-0555.
Di Dalmazi G, Fanelli F, Mezzullo M, et al. Steroid profiling by LC-MS/MS in nonsecreting and subclinical secreting adrenocortical adenomas. J Clin Endocrinol Metab. 2015;100(9):3529-3538. Doi: 10.1210/JC2015-1992.
Broussard JL, Kilkus JM, Delebecque F, et al. Elevetaed ghrelin predicts food intake during experimental sleep restriction. Obesity. 2016;24(1):132-138. Doi: 10.1002/oby.21321.
Pan W, Kastin AJ. Leptin: a biomarker for sleep disorders? Sleep Med Rev. 2014;18(3):283-290. Doi: 10.1016/j.smrv.2013.07.003.
Chin K, Shimizu K, Nakamura T, et al. Changes in intra-abdominal visceral fat serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation. 1999;100(7):706-712. Doi: 10.1161/01.cir.100.7.706.
Reiter RJ, Tan DX, Korkmaz A, et al. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. Ann Med. 2012;44(6):564-577. Doi:10.3109/07853890.2011.586365.
Agil A, Reiter RJ, Jimenez-Aranda, et al. Melatonin ameliorates low-grade inflammation and oxidative stress in young Zucker diabetic fatty rats. J Pineal Res. 2013;54(4):381-388. Doi: 10.1111/jpi.12012.
Touitou Y, Reinberg A, Toutiou D. Association between light at night, melatonin secretion, sleep deprivation, and internal clock: health impacts and mechanisms of circadian disruption. Life Sci. 2017;173:94-106. Doi: 10.1016/j.lfs.2017.02.008.
Cipolla-Neto J, Amaral FG, Afeche SC, et al. Melatonin, energy metabolism, and obesity: a review. Pineal Res. 2014;56(4):371-381. Doi: 10.1111/jpi.12137.
Muraki I, Wada H, Tanigawa T. Sleep apnea and type 2 diabetes. J Diabetes Investig. 2018;9(5):991-997. Doi: 10.1111/jdi.12823.
Reutrakul S, Mokhlesi B. Obstructive sleep apnea and diabetes. Chest. 2017;152(5):1070-1086. Doi: 10.1016/j.chest.2017.05.009.
Xu J, Long YS, Gozal D, et al. Beta-cell death and proliferation after intermittent hypoxia: role of oxidative stress. Free Radic Biol Med. 2009;46(6):783-790. Doi: 10.1016/j.freeradbiomed.2008.11.026.
Wang N, Khan SA, Prabhakar NR, et al. Impairment of pancreatic β-cell function by chronic intermittent hypoxia. Exp Physiol. 2013;98(9):1376-1385. Doi: 10.1113/expphysiol.2013.072454.
Polak J, Shimoda LA, Drager LF, et al. Intermittent hypoxia impairs glucose homeostasis in C57BL6/J mice: partial improvement with cessation of the exposure. Sleep. 2013;36(10):1483-1490;1490A-1490B. Doi: 10.5665/sleep.3040.
Gamboa A, Okamoto LE, Arnold AC, et al. Autonomic blockade improves insülin sensitivity in obese subjects. Hypertension. 2014;64(4):867-874. Doi: 10.1161/HYPERTENSIONAHA.114.03738.
Narkiewicz K, Kato M, Phillips BG, et al. Nocturnal continous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation. 1999;100(3):2332-2335. Doi: 10.1161/01.cir.100.2332.
Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol. 2010;44(2):87-97. Doi: 10.1677/JME-09-0063.
Boden G. Obesity, insülin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011;18(2):139-143. Doi: 10.1097/MED.0b013e3283444b09.
Li M, Li X, Lu Y. Obstructive sleep apnea syndrome and metabolic diseases. Endocrinology. 2018;159(7):2670-2675. Doi: 10.1210/en.2018-00248.
Grimaldi D, Beccuti G, Touma C, et al. Association of obstructive sleep apnea in rapid eye movement sleep with reduced glycemic control in type 2 diabetes: therapeutic implications. Diabetes Care. 2014;37(2):355-363. Doi: 10.2337/dc13-0933.
Bialasiewicz P, Czupryniak L, Pawlowski M, et al. Sleep disordered breathing in REM sleep reverses the downward trend in glucose concentration. Sleep Med. 2011;12(1):76-82. Doi: 10.1016/j.sleep.2010.04.017.
Silverberg DS, Oksenberg A. Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? Curr Hypertens Rep. 2001;3(3):209-215. Doi: 10.1007/s11906-001-0040-8.
Logan AG, Perlikowski SM, Mente A, et al. High prevalance of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19(12):2271-2277. Doi: 10.1097/00004872-200112000-00022.
Grote L, Hedner J, Peter JH. Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. J Hypertens. 2000;18(6):679-685. Doi: 10.1097/00004872-200018060-00004.
Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000;283(14):1829-1836. Doi: 10.1001/jama.283.14.1829.
Pedrosa RP, Drager LF, Gonzaga C, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertansion. Hypertension. 2011;58(5):811-817. Doi: 10.1161/HYPERTENSIONAHA.111.179788.
Marin JM, Agusti A, Villar I, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA. 2012;307(20):2169-2176. Doi: 10.1001/jama.2012.3418.
Alajmi M, Mulgrew AT, Fox J, et al. Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials. Lung. 2007;185(2):67-72. Doi: 10.1007/s00408-006-0117-x.
Narkiewicz K, Somers VK. The sympathetic nervous system and obstructive sleep apnea: implications for hypertension. J Hypertens. 1997;15(12 Pt 2):1613-1619. Doi: 10.1097/00004872-199715120-00062.
Rumantir MS, Jennings GL, Lambert GW, et al. The ‘adrenaline hypothesis’ of hypertension revisited: evidence for adrenaline release from the heart of petient with essential hypertension. J Hypertens. 2000;18(6):717-723. Doi: 10.1097/00004872-200018060-00009.
Xie A, Skatrud JB, Puleo DS, et al. Exposure to hypoxia produces long-lasting sympathetic activation in humans. J Appl Physiol (1985). 2001;91(4):1555-1562. Doi: 10.1152/jappl.2001.91.4.1555.
Tamisier R, Pepin JL, Remy J, et al. 14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. Eur Respir J. 2011;37(1):119-128. Doi: 10.1183/09031936.00204209.
Narkiewicz K, van de Borne PJ, Montano N, et al. Contribution of tonic chemoreflex activation to sympathetic avtivity and blood pressure in patients with obstructive sleep apnea. Circulation. 1998;97(10):943-945. Doi: 10.1161/01.cir.97.10.943.
Møller DS, Lind P, Strunge B, et al. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens. 2003;16(4):274-280. Doi: 10.1016/s0895-7061(02)03267-3.
Ma X, Abboud FM, Chapleau MW. A novel effect of angiotensin on renal sympathetic nerve activity in mice. J Hypertens. 2001;19(3 pt 2):609-618. Doi: 10.1097/200103001-00014.
Schulz R, Mahmoudi S, Hattar K,et al. enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continous positive airway pressure therapy. Am J Respir Crit Care Med. 2000;162(2 pt 1)566-570. Doi: 10.1164/ajrccm.162.2.990891.
Jelic S, Padeletti M, Kawut SM, et al. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulaton. 2008;117(17):2270-2278. Doi: 10.1161/CIRCULATIONAHA.107.741512.
Wilcox CS. Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep. 2002;4(2):160-166. Doi: 10.1007/s11906-002-0041-2.
Troncoso Brindeiro CM, da Silva AQ, Allahdadi KJ, et al. Reactive oxygen species contribute to sleep apnea-induced hypertension in rats. Am J Physiol Heart Circ Physiol. 2007;293(5):H2971-2976. Doi: 10.1152/ajpheart.00219.2007.
Savransky V, Nanayakkara A, Li J, et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Crit Care Med. 2007;175(12):1290-1297. Doi: 10.1164/rccm.200612-1771OC.
Perry JC, D’Almeida V, Souza FG, et al. Consequences of subchronic and chronic exposure to intermittent hypoxia and sleep deprivation on cardiovascular risk factors in rats. Respir Physiol Neurobiol. 2007;156(3):250-258. Doi: 10.1016/j.resp.2006.10.004.
Li J, Bosch-Marce M, Nanayakkara A, et al. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxi-inducible factor-1alpha. Physiol Genomics. 2006;25(3):450-457. Doi: 10.1152/physiolgenomics.00293.2005.
Ntambi JM, Miyazaki M. Regulation of stearoyl-CoA desturases and role in metabolism. Prog Lipid Res. 2004;43(2):91-104. Doi: 10.1016/s0163-7827(03)00039-0.
Chopra S, Rathore A, Younas H, et al. Obstructive sleep apnea dynamically increases nocturnal plasma free fatty acids, glucose, and cortisol during sleep. J Clin Endocrinol Metab. 2017;102(9):3172-3181. Doi: 10.1210/jc.2017-00619.
Xu H, Yi H, Guan J, et al. Effect of contiuous positive airway pressure on lipid profile in patients with obstructive sleep apnea syndrome: a meta-analysis of randomized controlled trials. Atherosclerosis. 2014;234(2):446-453. Doi: 10.1016/j.atherosclerosis.2014.03.034.
Minoguchi K, Yokoe T, Tazaki T, et al. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med. 2005;172(5):625-630. Doi: 10.1164/rccm.200412-1652OC.
Drager LF, Bortolotto LA, Figueiredo AC, et al. effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2007;176(7):706-712. Doi: 10.1164/rccm.200703-500OC.
Peker Y, Kraiczi H, Hedner J, et al. An independent association between obstructive sleep apnoea and coronary artery disease. Eur Respir J. 1999;14(1):179-184. Doi:10.1034/j.1399-3003.1999.14a30x.
Gottlieb DJ, Yenokyan G, Newman AB, et al. prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122(4):352-360. Doi: 10.1161/CIRCULATIONAHA.109.901801.
Lutsey PL, McClelland RL, Duprez D, et al. Objectively measured sleep characteristics and prevalence of coronary artery calcification: the multi-ethnic study of atherosclerosis sleep study. Thorax. 2015;70(9):880-887. Doi: 10.1136/thoraxjnl-2015-206871.
Sert Kuniyoshi FH, Garcia-Touchard A, Gami AS, et al. Day-night variation of acute myocardial infarction in obstructive sleep apnea. J Am Coll Cardiol. 2008;52(5):343-346. Doi: 10.1016/j.jacc.2008.04.027.
Yumino D, Tsurumi Y, Takagi A, et al. Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. Am J Cardiol. 2007;99(1):26-30. Doi:10.1016/j.amjcard.2006.07.055.
Sert Kuniyoshi FH, Singh P, Gami AS, et al. Patients with obstructive sleep apnea exhibit impaired endothelial function after myocardial infarction. Chest. 2011;140(1):62-67. Doi: 10.1378/chest.10-1722.
Thunström E, Glantz H, Fu M, et al. Increased inflammatory activity in nonobese patients with coronary artery disease and obstructive sleep apnea. Sleep. 2015;38(3):463-471. Doi: 10.5665/sleep.4510.
Cassar A, Morgenthaler TI, Lennon RJ, et al. Treatment of obstructive sleep apnea is associated with decreased cardiac death after percutaneous intervention. J Am Coll Cardiol. 2007;50(14):1310-1314. Doi: 10.1016/j.jacc.2007.06.028.
Fu Y, Xia Y, Yi H, et al. Meta-analysis of all-cause and cardiovascular mortality in obstructive sleep apnea without contiuaous positive airway pressure treatment. Sleep Breath. 2017;21(1):181-189. Doi: 10.1007/s11325-016-1393-1.
Peker Y, Glantz H, Eulenburg C, et al. Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with nonsleepy obstructive sleep apnea. The RICCADSA randomized control trial. Am J Respir Crit Care Med. 2016;194(5):613-620. Doi: 10.1164/rccm.201601-0088OC.
